trial

Study on Metabolic Parameters of Sertindole in Patients With Schizophrenia

NCTId NCT00759460
as of 2026-07-01
Add to landscapeMonitor thisAsk about this
at a glance
Phase 3 · Completed
Enrollment 250 (actual)
Sponsored by H. Lundbeck A/S
Primary completion 2008-03
Synthesized from structured facts only — each point cited above.

Design & status

Phase
Phase 3
Status
Completed
Enrollment
250 (actual)
Study type
Interventional
Allocation
Randomized
Model
Parallel
Masking
Double
Start
2007-03
Primary completion
2008-03
Eligibility
ALL · 18 Years · 65 Years

Interventions & indications

Drugs
SertindoleOlanzapine

Sponsors

H. Lundbeck A/SLead Sponsor

Sites

1 total
Beijing, China

Linked catalysts

1
Study on Metabolic Parameters of Sertindole in Patients With Schizophrenia — primary completion2008-03

Facts & assertions

4 sourced
Enrollment
250
Phase
PHASE3
Primary Completion Date
2008-03
Status
COMPLETED
relationships
The graph out of here
drug
Sertindole
drug
Olanzapine
drug
lead_sponsor
H. Lundbeck A/S
company
indication
Schizophrenia
indication
Schizophrenia
indication